Nekrasov
Arkady Nekrasov

Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of the State Prize of the Russian Federation.

  • Company foundation.
  • Registration of the Polyoxidonium® medicine and the Grippol® vaccine.
  • Opening of the production facilities for manufacture of APIs, soft and solid dosage forms, and injectable forms.
  • The beginning of the partnership with Solvay Pharma (currently, Abbott).
  • Assignment of the International Non-proprietary Name - Azoximer bromide for Polyoxidonium® by WHO.
Полиоксидоний - таблетки 12 мг - Вправо.jpgThe State Prize of the Russian Federation awarded to the team of creators and developers led by Proffessor A.V. Nekrasov for the creation of innovative medicines Polyoxidonium® and Grippol® and for their implementation in healthcare practice.
  • Market launch of Longidaza®.
  • Opening of a modern technological manufacturing and warehouse complex in Moscow Region, complying with GMP standards.
  • Market launch of the first Russian influenza vaccine Grippol® Plus in pre-filled syringes.
  • Development and production of vaccines against pandemic strain of influenza A/H1N1: MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • Annual production of Grippol® Plus vaccine for the National Immunization Schedule.
  • Launch of a localization project of the 13-valent conjugate pneumococcal vaccine manufacturing (in cooperation with Pfizer).
  • Obtaining EU GMP certificates (Slovakia), the beginning of export of Polyoxidonium® to the European Union.
  • Petrovax becomes a part of the Interros Group.
  • Market launch of Imoferaza® cosmetic cream.
  • Assignment of the International Non-proprietary Name - bovhyaluronidase azoximer for Longidaza® by WHO.
  • The beginning of cooperation with Boehringer Ingelheim to localize full-cycle production of innovative thrombolytic medicines Metalyse® and Actilyse®.
  • Start of export of Grippol® Plus vaccine.

Grippol Welson

  • Market launch of Grippol® Quadrivalent, Russian first quadrivalent inactivated subunit adjuvanted influenza vaccine.
  • Expanding the portfolio with a new product - Velson® (INN: Melatonin).
  • Successful completion of a post-registration study (PASS) of Polyoxidonium® in Europe (Slovakia).

  • Market launch of new products: Uronext®, VitaFerr®, Gialera®, ARTNEO®.
  • Obtaining USA, Indian, South Korean and EU patents for Longidaza®.
  • Production expansion: opening of the 4th line of production for manufacturing of injectable dosage forms, start of construction of new biotechnological complex.
  • The beginning of cooperation with ISU ABXIS (South Korea) to localize production of medicine for orphan therapy — Fabry disease.
  • Сhange in the composition of shareholders — Interros Group left the membership of the company.
  • Large-scale clinical trials program of Polyoxidonium® and Longidaza® in the prevention and treatment of COVID-19.
  • Project for the development and manufacture of the vaccine against COVID-19 — Convidecia — in cooperation with CanSino Biologics Inc.


© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.